AZTA Azenta, Inc. - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
AZTA Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Medical Instruments & Supplies
Current Price
Live
$40.05
Analyst Target
$43.5
+8.6%
Upside
52W High
$55.64
52W Low
$23.91
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$1.84B
P/E
77.02
ROE
1.4%
Profit margin
-9.4%
Debt/Equity
0.03
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
65%
Analysis Accuracy
AZTA exhibits mixed financial health with a weak Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score to assess distress risk. While the company shows strong revenue visibility and improving earnings trends, elevated valuation metrics (P/E of 77.02 vs. sector average of 220.68) and negative profit margins (-9.39%) raise concerns. Recent insider selling and declining long-term price performance contrast with a positive short-term rebound and solid quarterly earnings surprises. The stock trades significantly above the Graham Number of $20.99, suggesting potential overvaluation relative to defensive criteria.
Key Strengths
Strong gross margin of 45.52%, indicating pricing power or efficient cost control in core operations
Solid balance sheet with low debt/equity (0.03) and strong liquidity (current ratio: 2.98)
Recent earnings momentum with 4 of the last 5 quarters beating estimates by double digits
Revenue growth of 5.20% YoY in a challenging healthcare environment
Trading below analyst target price of $43.50, offering modest upside potential
Key Risks
Weak Piotroski F-Score of 4/9 signals suboptimal financial strength and profitability concerns
Negative net profit margin (-9.39%) and ROA (-0.65%) indicate ongoing profitability challenges
Elevated P/E ratio of 77.02, which may not be sustainable if earnings growth falters
Insider selling activity over the past 6 months suggests lack of confidence from executives
Long-term price performance is deeply negative: -50.6% over 5 years
AI Fair Value Estimate
Based on comprehensive analysis
$28.5
-28.8% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
44
Moderate
42
64
55
50
10
AI Verdict
Neutral with upside risk if earnings growth accelerates
Key drivers: Improving earnings trajectory, Low leverage, High gross margin, Rich valuation, Weak profitability metrics
Confidence
70%
Value
42/100
Ref P/E, PEG, Graham Number
Positives
- Price/Sales of 3.10 is reasonable for a healthcare equipment firm
- Below-average P/E relative to sector average of 220.68
Watchpoints
- Current price ($40.05) is nearly double the Graham Number ($20.99)
- High P/E of 77.02 despite unproven earnings sustainability
- No PEG ratio due to inconsistent earnings
Future
64/100
Ref Growth rates
Positives
- Recent YoY EPS growth of 16.7%
- Q/Q EPS growth of 10.5%
- Consistent revenue growth and beat rates suggest forward momentum
Watchpoints
- Forward P/E of 39.46 still high for a company with negative net margins
- No official earnings growth guidance provided
Past
55/100
Ref Historical trends
Positives
- History of large earnings surprises (e.g., +699.9% in Q3 2023)
- Revenue growth has been positive for multiple quarters
Watchpoints
- 5-year price return of -50.6% reflects poor investor returns
- Several quarters with negative EPS and earnings misses
Health
50/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 2.98 and quick ratio of 2.23 indicate strong short-term liquidity
- Very low debt/equity ratio of 0.03 reduces solvency risk
Watchpoints
- Piotroski F-Score of only 4/9 indicates weak financial health
- Negative ROE (1.40%) and ROA (-0.65%) reflect poor capital efficiency
- No Altman Z-Score available limits distress risk assessment
Dividend
10/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend program (yield: N/A)
- Dividend strength score of 0/100
- Payout ratio is 0%, indicating no return of capital to shareholders
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$40.05
Analyst Target
$43.5
Upside/Downside
+8.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AZTA and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AZTA
Azenta, Inc.
Primary
|
-50.6% | -29.6% | -26.9% | +16.3% | +16.1% | +0.1% |
|
ANAB
AnaptysBio, Inc.
Peer
|
+227.2% | +183.1% | +284.9% | +177.0% | +17.3% | +17.0% |
|
AVAH
Aveanna Healthcare Holdings Inc.
Peer
|
-27.7% | +583.5% | +75.7% | +119.2% | -0.3% | -5.9% |
|
ADUS
Addus HomeCare Corporation
Peer
|
-6.0% | +1.0% | +11.6% | -8.1% | -10.1% | -1.8% |
|
AUPH
Aurinia Pharmaceuticals Inc.
Peer
|
-22.4% | +77.0% | +81.0% | +62.7% | -10.7% | -2.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
77.02
Forward P/E
39.46
PEG Ratio
N/A
P/B Ratio
1.06
P/S Ratio
3.1
EV/Revenue
2.63
EV/EBITDA
39.43
Market Cap
$1.84B
Profitability
Profit margins and return metrics
Profit Margin
-9.39%
Operating Margin
1.12%
Gross Margin
45.52%
ROE
1.4%
ROA
-0.65%
Growth
Revenue and earnings growth rates
Revenue Growth
+5.2%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.03
Low debt
Current Ratio
2.98
Strong
Quick Ratio
2.23
Excellent
Cash/Share
$7.41
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-04
$N/A
2025-11-21
$0.21
+7.3% surprise
2025-08-05
$0.19
+39.0% surprise
2025-05-07
$0.05
-31.8% surprise
Healthcare Sector Comparison
Comparing AZTA against 147 companies in the Healthcare sector
(10 bullish, 55 neutral, 82 bearish)
P/E Ratio
77.02
This Stock
vs
164.56
Sector Avg
-53.2%
(Discount)
Return on Equity (ROE)
1.4%
This Stock
vs
-52.77%
Sector Avg
-102.7%
(Below Avg)
Profit Margin
-9.39%
This Stock
vs
-20.78%
Sector Avg
-54.8%
(Weaker)
Debt to Equity
0.03
This Stock
vs
6.16
Sector Avg
-99.4%
(Less Debt)
Revenue Growth
5.2%
This Stock
vs
137.39%
Sector Avg
-96.2%
(Slower)
Current Ratio
2.98
This Stock
vs
3.36
Sector Avg
-11.3%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AZTA
Azenta, Inc.
|
NEUTRAL | $1.84B | 77.02 | 1.4% | -9.4% | $40.05 | |
|
ANAB
AnaptysBio, Inc.
|
BULLISH | $1.86B | - | -24.5% | -5.6% | $64.81 | |
|
AVAH
Aveanna Healthcare Holdings Inc.
|
NEUTRAL | $1.81B | 23.46 | -% | 3.3% | $8.68 | |
|
ADUS
Addus HomeCare Corporation
|
NEUTRAL | $1.88B | 19.42 | 9.3% | 6.7% | $101.35 | |
|
AUPH
Aurinia Pharmaceuticals Inc.
|
NEUTRAL | $1.92B | 26.42 | 20.7% | 29.3% | $14.53 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-24 | MAROTTA JOHN | Chief Executive Officer | Stock Award | 122,269 | - |
| 2025-11-24 | MAROTTA JOHN | Chief Executive Officer | Stock Award | 118,194 | - |
| 2025-11-24 | ZHOU GINGER | Officer | Stock Award | 13,042 | - |
| 2025-11-24 | PIROGOVA OLGA | Officer | Stock Award | 16,303 | - |
| 2025-11-24 | LIN LAWRENCE Y | Chief Financial Officer | Stock Award | 36,681 | - |
| 2025-11-24 | STARR EPHRAIM | General Counsel | Stock Award | 34,235 | - |
| 2025-09-10 | MAROTTA JOHN | Chief Executive Officer | Sale | 316 | $9,294 |
| 2025-08-12 | ZHOU GINGER | Officer | Sale | 1,085 | $30,966 |
| 2025-08-12 | PIROGOVA OLGA | Officer | Sale | 1,085 | $30,966 |
| 2025-08-11 | LIN LAWRENCE Y | Chief Financial Officer | Purchase | 2,500 | $69,900 |
| 2025-08-11 | LIN LAWRENCE Y | Chief Financial Officer | Purchase | 2,500 | $69,900 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
6 analysts
TD Cowen
2026-01-08
Hold
Hold
Evercore ISI Group
2026-01-05
In-Line
Outperform
Needham
2025-12-19
Buy
Buy
Raymond James
2025-11-25
Outperform
Outperform
Needham
2025-11-21
Buy
Buy
Jefferies
2025-10-30
Hold
Buy
Raymond James
2025-08-06
Market Perform
Outperform
Evercore ISI Group
2025-08-05
In-Line
In-Line
Past News Coverage
Recent headlines mentioning AZTA from our newsroom.
Newest → oldest
No matching news yet.